Celularity Inc
No SEC Form 4 filings for $CELU in the last 30 days.
See all $CELU insider activity →Celularity Inc reported 2Q 2026 revenue of $5.43M, down 5.3% YoY, and net income of $0.55M, a turnaround from a $24.52M loss in 2Q 2025. Diluted EPS was $0.02, improved from ($1.02) YoY. Revenue mix shifted to product sales, while license/royalty revenue declined. The company completed the sale of NexGel biomaterials and focused on core cellular therapy programs.
Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Celularity Announces Naveen Jain to Join Board of Directors Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBENEWSWIRE) — Celularity Inc. (
Celularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 23, 2026, Celularity Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers party thereto (collectively, the “Purchasers”),
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CELU (Celularity Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CELU coverage spans corporate actions, regulation and earnings.
Earnings beat expectations with a profit swing, likely supporting short-term upside.
Board addition of a high‑profile tech entrepreneur may be viewed positively by investors.
The financing adds cash but introduces dilution and senior debt, likely weighing on the stock short term.
The new capital improves liquidity and funds manufacturing expansion.
Regaining Nasdaq compliance removes a potential delisting risk and may improve investor confidence.
AlphAI scores every news story that mentions CELU with an AI model for sentiment and relevance, and aggregates insider trades from Celularity Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Celularity Inc reported 2Q 2026 revenue of $5.43M, down 5.3% YoY, and net income of $0.55M, a turnaround from a $24.52M loss in 2Q 2025. Diluted EPS was $0.02, improved from ($1.02) YoY. Revenue mix shifted to product sales, while license/royalty revenue declined. The company completed the sale of NexGel biomaterials and focused on core cellular therapy programs.
1 min readCelularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Celularity Announces Naveen Jain to Join Board of Directors Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBENEWSWIRE) — Celularity Inc. (
1 min readCelularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 23, 2026, Celularity Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers party thereto (collectively, the “Purchasers”),
1 min readCelularity Inc. (CELU) raised over $10 million in initial financing, part of a $28 million recapitalization plan. The funds will support commercial execution and manufacturing. The company aims for positive cash flow by Q1 2027, reduced monthly cash burn, and increased revenue. CELU stock is up 13.04% to $1.30.
2 min readCelularity Inc (CELU) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 11, 2026, Celularity Inc. (“Celularity”) received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that Celularity has regained compliance with the minimum bid price requirement
1 min readGilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readCelularity (CELU) partners with MuseCell Innovations to manufacture Dezawa MuseCells in the U.S. The deal could generate $300M in purchases over five years. Celularity's stock is up 64.70% to $1.48.
2 min readSummit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readCelularity Inc. (CELU) received a Nasdaq notice for late quarterly filings, failing to submit reports for Q1 and Q2 2026. The company has until September 4 to submit a compliance plan. Trading continues on Nasdaq under 'CELU'. Celularity is working to file the reports promptly.
1 min readCelularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, Celularity Inc. (the “Company”) terminated the employment of Rick Gonzalez, the Company’s Chief Commerc
2 min read
